Keywords: ارلوتینیب; Gold nanoparticles; SERS; Therapeutic drug monitoring; Erlotinib; Competitive reactions;
مقالات ISI ارلوتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ارلوتینیب; Erlotinib; Enzyme-linked immunosorbent assay; O-desmethyl erlotinib; Tyrosine-kinase inhibitor;
Keywords: ارلوتینیب; NSCLC; non-small cell lung cancer; RCTs; randomized controlled trials; OS; overall survival; PFS; progression free survival; ORR; objective response rate; AEs; adverse effects; HR; hazard ratio; RR; relative risk; CI; confidence intervals; FDA; Food and D
Keywords: ارلوتینیب; Erlotinib; Bovine serum albumin (BSA); Surface plasmon resonance; Enthalpy; Entropy; Molecular docking;
Keywords: ارلوتینیب; Erlotinib; Fulvestrant; Lung cancer; EGFR; Estrogen; Estrogen receptor;
Keywords: ارلوتینیب; Carcinoma; Chemotherapy; Erlotinib; Gefitinib; Targeted therapy;
Keywords: ارلوتینیب; Erlotinib; Genistein; Probe-sonication; Impactor; Nebuliser;
Keywords: ارلوتینیب; Gefitinib; Erlotinib; Resveratrol; Chalcones; Quinazolines; Cytotoxicity;
Keywords: ارلوتینیب; HER3; human epidermal growth factor receptor 3; NSCLC; non-small cell lung cancer; HRG; heregulin; EGFR; epidermal growth factor receptor; ITT; intent-to-treat; qRT-PCR; quantitative reverse transcription polymerase chain reaction; Patritumab; Erlotinib;
Keywords: ارلوتینیب; Retinoblastoma; Erlotinib; Cancer proliferation; Cancer migration; Cancer graft;
Keywords: ارلوتینیب; Erlotinib; OSI420; Paracetamol; Paracetamol glucuronide; Paracetamol sulphate;
Keywords: ارلوتینیب; Nanoparticle; Combination therapy; Sequential delivery; Triple negative breast cancer; EGFR inhibitor; Erlotinib; Doxorubicin;
Keywords: ارلوتینیب; EGFR testing; Erlotinib; Health services research; MarketScan data; Population-based study;
Keywords: ارلوتینیب; Non-small cell lung cancer; Chemotherapy; Second-line treatment; Docetaxel; Pemetrexed; Erlotinib;
Keywords: ارلوتینیب; Erlotinib; Vascular normalization; Tumor microenvironment; Nanomedicine; Immunotherapy;
Keywords: ارلوتینیب; Afatinib; Erlotinib; Gefitinib; Mutation; NSCLC;
Keywords: ارلوتینیب; Erlotinib; Tyrosine kinase inhibitor; Pancreatic cancer; Phospholipid complex; Solubility enhancement; Oral bioavailability;
Keywords: ارلوتینیب; Non-small cell lung cancer; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitors (TKI); TKI resistance; Osimertinib; Gefitinib; Erlotinib; Afatinib;
Keywords: ارلوتینیب; Crizotinib; Erlotinib; Phase I combination trial; MET inhibitor; EGFR inhibitor;
Keywords: ارلوتینیب; ACL; Aceclofenac; AUC; area under the curve; BBB; blood-brain barrier; BCS; Biopharmaceutical classification system; BVC; bupivacaine; CNS; central nervous system; CUR; Curcumin; DMBA; 7,12-dimethylbenzanthracene; DOX; doxorubicin; DSPE-PEG2000; 1,2-diste
Keywords: ارلوتینیب; Adenocarcinoma; Capecitabine; Erlotinib; Gemcitabine; Nab-paclitaxel; Oxaliplatin; Pancreas; Pneumonitis;
Keywords: ارلوتینیب; Bevacizumab; Colorectal cancer; Efatutazone; EGFR inhibitors; Erlotinib; Maintenance; MGN1703; Treatment duration;
Keywords: ارلوتینیب; Drug-drug interaction; Erlotinib; Phenytoin;
Keywords: ارلوتینیب; Cytostatic agents; Emerging contaminants; Environmental samples; Liquid chromatography; Gas chromatography; 5-FU; 5-Fluorouracil; ACT-D; actinomycin-D; A-GLU; Aminoglutethimide; APCI; atmospheric pressure chemical ionization; APPI; atmospheric pressure ph
Keywords: ارلوتینیب; EGFR; Erlotinib; Smooth muscle cell; Monocyte; Macrophage; Chronic allograft injury;
Keywords: ارلوتینیب; epidermal growth factor receptor; epidermal growth factor receptor inhibitor; erlotinib; squamous cell carcinoma of the skin; CR; complete response; EGFR; epidermal growth factor receptor; EGFRi; epidermal growth factor receptor inhibitors; mTOR; mechanis
Keywords: ارلوتینیب; Tyrosine; Signaling; Phosphoproteomics; Cancer; EGFR; Erlotinib
Keywords: ارلوتینیب; Dovitinib; Erlotinib; TKI 258; NSCLC; Epidermal growth factor receptor (EGFR);
Keywords: ارلوتینیب; Drug interactions; Erlotinib; Histamine type-2 receptor antagonist; Non-small cell lung cancer; Proton pump inhibitors
Keywords: ارلوتینیب; Modeling; NSCLC; PET; Survival; Erlotinib;
Keywords: ارلوتینیب; EGFR; ACC; Sunitinib; Erlotinib;
Keywords: ارلوتینیب; Non-small cell lung cancer; Epidermal growth factor receptor; Histone deacetylase inhibitor; Epigenetics; Clinical trial; Erlotinib; Romidepsin;
Keywords: ارلوتینیب; EGFR; Erlotinib; TKI; Genetic polymorphisms; Treatment response; Survival;
Keywords: ارلوتینیب; Erlotinib; Thoracic radiotherapy; Radiation pneumonitis; NSCLC;
Keywords: ارلوتینیب; Epidermal growth factor receptor; Tyrosine kinase inhibitors; EGFR-TKI; Gefitinib; Erlotinib; Lung cancer; Pregnancy; Pharmacology
Keywords: ارلوتینیب; cholinergic effect; electrical field stimulation; erlotinib; tracheal smooth muscle
Keywords: ارلوتینیب; ARQ197; EGFR pathway; Erlotinib; MET pathway; Tivantinib
Keywords: ارلوتینیب; Non–small-cell lung cancer; Apricoxib; Erlotinib; Cyclooxygenase-2 inhibitor; Prostaglandin E2 metabolite
Keywords: ارلوتینیب; Oral premalignant lesions; Leukoplakia; Chemoprevention; Epidermal growth factor receptor; Erlotinib; Cetuximab
Keywords: ارلوتینیب; Erlotinib; Diarrhea; ER stress; E-cadherin; Apoptosis
Keywords: ارلوتینیب; Head and neck cancer; EGFR; Apoptosis; Radiosensitivity; Cetuximab; Erlotinib;
Keywords: ارلوتینیب; Afatinib; Chemotherapy; Dacomitinib; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non-small cell lung cancer; Pharmacokinetics; Tyrosine kinase inhibitors;
Keywords: ارلوتینیب; Meta-analysis; Lung cancer; Gefitinib; Afatinib; Erlotinib; Ethnicity; Trial design;
Keywords: ارلوتینیب; Erlotinib; Bevacizumab; Non-squamous; Non-small cell lung cancer; First-line; Combination therapy;
Keywords: ارلوتینیب; acneiform rash; cutaneous side effects; epidermal growth factor receptor inhibitor; erlotinib; Japanese patients; non-small cell lung cancer; prevention; skin toxicities; ADL; activities of daily living; AEs; adverse events; BSA; body surface area; CI; co
Keywords: ارلوتینیب; Biomarker; Contractility; Erlotinib; FCCP; Isolated heart; Isoproterenol; Rat; Sorafenib; Sunitinib; Verapamil;
Keywords: ارلوتینیب; Health-related quality of life; Metastatic non-small-cell lung cancer; Erlotinib;
Keywords: ارلوتینیب; Erlotinib; OSI420; Diabetes; Pharmacokinetics; Rabbit
Keywords: ارلوتینیب; Medication-taking; Grounded theory; Non-small cell lung cancer; Erlotinib; Epidermal growth factor receptor
The redox mechanism investigation of non-small cell lung cancer drug: Erlotinib via theoretical and experimental techniques and its host-guest detection by β-Cyclodextrin nanoparticles modified glassy carbon electrode
Keywords: ارلوتینیب; Anticancer drug; Erlotinib; Adsorptive stripping square wave voltammetry; β-Cyclodextrin; Electronic properties; Computational analysis;